Page last updated: 2024-11-12

18-methoxycoronaridine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

18-methoxycoronaridine: a naturally-occurring iboga alkaloid; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID10248465
SCHEMBL ID21359469
MeSH IDM0270261

Synonyms (7)

Synonym
bdbm50129749
18-methoxycoronaridine
308123-60-6
DTXSID40437331
SCHEMBL21359469
Q200107
methyl (1s,17r)-17-(2-methoxyethyl)-3,13-diazapentacyclo[13.3.1.02,10.04,9.013,18]nonadeca-2(10),4,6,8-tetraene-1-carboxylate

Research Excerpts

Dosage Studied

Recent studies demonstrated that pretreatment with the putative antiaddictive agent, ibogaine (IBO), and a synthetic iboga alkaloid congener, 18-methoxycoronaridine (18-MC), increase the potency of cocaine to elicit behavioral sensitization. The effect proposed to contribute, in part, to their ability to attenuate drug self-administration.

ExcerptRelevanceReference
" 18-Methoxycoronaridine produced a downward shift in the entire morphine dose-response curve without any displacement to the left or right."( Attenuation of the reinforcing efficacy of morphine by 18-methoxycoronaridine.
Glick, SD; Maisonneuve, IM, 1999
)
1.46
" Compared to vehicle pretreated controls, 18-MC increased the potency of morphine, shifting the dose-response curve to the left, in acute morphine treated rats; however, 18-MC did not alter the potency of morphine in rats treated repeatedly with morphine."( The potential anti-addictive agent, 18-methoxycoronaridine, blocks the sensitized locomotor and dopamine responses produced by repeated morphine treatment.
Glick, SD; Maisonneuve, IM; Szumlinski, KK, 2000
)
0.58
" Recent dose-response studies demonstrated that pretreatment with the putative antiaddictive agent, ibogaine (IBO), and a synthetic iboga alkaloid congener, 18-methoxycoronaridine (18-MC), increase the potency of cocaine to elicit behavioral sensitization, an effect proposed to contribute, in part, to their ability to attenuate drug self-administration."( Interactions between iboga agents and methamphetamine sensitization: studies of locomotion and stereotypy in rats.
Balogun, MY; Glick, SD; Maisonneuve, IM; Szumlinski, KK, 2000
)
0.5
" However oral dosing is the preferred route clinically."( Acute oral 18-methoxycoronaridine (18-MC) decreases both alcohol intake and IV nicotine self-administration in rats.
Cauley, MC; Glick, S; Levin, ED; Rezvani, AH; Rose, JE; Slade, S; Wells, C,
)
0.52
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (52)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's7 (13.46)18.2507
2000's25 (48.08)29.6817
2010's18 (34.62)24.3611
2020's2 (3.85)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 56.06

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index56.06 (24.57)
Research Supply Index3.99 (2.92)
Research Growth Index4.52 (4.65)
Search Engine Demand Index91.05 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (56.06)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (3.77%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other51 (96.23%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]